Partners PrEP and TDF2: new data shows oral TDF and TDF/FTC effective in men and women
- Statements are available from AVAC and the trial sponsors (The University of Washington and the CDC).
- For more background on the trials and on PrEP, click here.
iPrEx: daily TDF/FTC in gay men and transgender women reduces risk by 44% overall
CAPRISA 004: topical 1% tenofovir gel applied vaginally within 12 hours before and after sex reduces women's risk by 38%
FEM-PrEP: trial closes due to futility—data review committee says it will not be able to answer the question
- AVAC's statement on the trial closure
- Read AVAC's Frequently Asked Questions (FAQ) about FEM-PrEP
- FHI has a statement and a number of helpful fact sheets (including adherence and pregnancy and contraceptive effectiveness in the FEM-PrEP trial) available here
- Statements are also available from IPM, IAVI, MTN, CAPRISA, MDP and the CDC
- Read AVAC's Fact Sheet on Data Safety Monitoring Boards (DSMBs)
VOICE: the data review committee recommended that the 1% tenofovir gel arm of the study be stopped because it was safe but not effective
- MTN Statement
and Answers document on DSMB decision (from
- AVAC Statement
- Listen to a recording of a global teleconference to discuss this development
TrialsThis section provides information on ongoing PrEP trials and trial results to date.
PrEP is an experimental approach that would use antiretroviral medications (ARVs) to reduce the risk of HIV infection in HIV-negative people.
HIV Prevention Research and Development
Database (PxRD) provides up-to-date
information and links to product specific pages
for in-depth information on trials and
- Trial Results: This section includes information on the results of the trials, both as AVAC covered the releases in real-time and journal articles that include additional data analyses.
Trials: Information on future PrEP
trials is available